OHMX.bio, based in Ghent, Belgium, specializes in providing a comprehensive research and development (R&D) platform to address complex biological questions. The company leverages advanced technologies across various omics fields such as epigenomics, transcriptomics, translatomics, and proteomics. Key offerings include ribosome profiling, third-generation sequencing, and single-cell omics solutions. OHMX.bio serves a diverse clientele, including academic researchers, biotech firms, and clinical diagnostics companies, operating primarily in the life sciences and healthcare markets.

The business model of OHMX.bio revolves around offering specialized R&D services and solutions that help clients accelerate their research and achieve more accurate results. Revenue is generated through service contracts, partnerships, and grants. Notably, OHMX.bio is an official partner of Oxford Nanopore Technologies, providing a range of sequencing platforms that offer full-length characterization without fragmentation or amplification, thus eliminating sources of bias.

OHMX.bio's commitment to innovation is further evidenced by its receipt of a €720K grant in collaboration with Fujirebio Europe and its active participation in various industry events and conferences.

Keywords: R&D platform, omics solutions, epigenomics, transcriptomics, translatomics, proteomics, ribosome profiling, third-generation sequencing, single-cell omics, Oxford Nanopore Technologies.